A successful strategy in the development of antiretroviral drugs has been the targetting of the virally encoded reverse transcriptase (RT) (De Clercq, 1998; Artico, 1996). Two classes of compounds potently and selectively inhibit this enzyme: nucleoside and non-nucleoside reverse transcrip-tase inhi...
| Other Authors: | |
|---|---|
| Format: | Text |
| Language: | English |
| Subjects: | |
| Online Access: | http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.816.5630 http://avc.sagepub.com/content/12/1/37.full.pdf |
| Summary: | A successful strategy in the development of antiretroviral drugs has been the targetting of the virally encoded reverse transcriptase (RT) (De Clercq, 1998; Artico, 1996). Two classes of compounds potently and selectively inhibit this enzyme: nucleoside and non-nucleoside reverse transcrip-tase inhibitors (NRTIs and NNRTIs, respectively). Both play an important role in the combination therapy for HIV infection/AIDS. To date, three NNRTIs are available for clinical use: nevirapine, delavirdine and efavirenz. However, new NNRTIs that show better activity against clinically rele-vant resistant mutants are needed. Since 1992, our group has been developing dihydro-alky- |
|---|